Trial · NCT04555343
Intravesical Antifibrinolytic for Patients With Hematuria and Clot Retention
NCT04555343, Phase 1, Phase 2, Completed, Fraser Health
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Intravesical Antifibrinolytic for Patients With Hematuria and Clot Retention. Trials, record NCT04555343. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04555343
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Intravesical Antifibrinolytic for Patients With Hematuria and Clot Retention
- NCT number
- NCT04555343
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 14 participants, actual
- Lead sponsor
- Fraser Health
- Conditions
- Urologic Diseases, Prostate Cancer, Bladder Cancer, Urinary Retention, Hematuria, Nurse Physician Relations, Nurse's Role, Patient Satisfaction
- Interventions
- Tranexamic acid
- First posted
- 2020-09-18
- Last updated
- 2021-11-05
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Acceptability of study procedures to participants as assessed by successful consenting retention | 20 patients total or a maximum of six months | measured by the number of eligible patients and number that consent to the study intervention |
| Primary | Participant recruitment time as measured by the time between identification of patient to consent completion | 20 patients total or a maximum of six months | Patient triage time will be compared to time consent was obtained |
| Primary | Times to intervention- measured by time from consent to time intervention initiated | 20 patients total or a maximum of six months | all participants will have consent and intervention time documented |
| Secondary | Trial site appropriateness as measured by total number of participants recruited within study time | 20 patients total or a maximum of six months | Both sites will document total number of patients recruited within study time |
| Secondary | Incidence of treatment emergent adverse events as assessed by the CTCAE v3.0 severity scale | 20 patients total or a maximum of six months | All participants will be followed throughout their hospital admission and all adverse events will be documented. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04555343
GET https://conductscience.org/api/trials/v1/NCT04555343/registered